Shaker A. Mousa

Oncology · 2012–2016

A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Shaker A. Mousa trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll

Papers from Shaker A. Mousa's perspective

Ordered by how strongly the researchers Shaker A. Mousa trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  2. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  3. BRAF and RAS mutations in human lung cancer and melanoma. (Cancer Research)
  4. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. (New England Journal of Medicine)
  5. Mutations of the BRAF gene in human cancer (Nature)
  6. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma (Proceedings of the National Academy of Sciences of the United States of America)
  7. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. (New England Journal of Medicine)
  8. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. (Journal of Clinical Oncology)
  9. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. (Cancer Research)
  10. Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer (New England Journal of Medicine)

Their papers